文献速递消化系统肿瘤

avelumab对比化疗三线治疗晚期胃癌的III期随机试验JAVELIN Gastric 300

Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.
PubMed 文献 · Ann Oncol · 2018-01-01

JAVELIN Gastric 300研究在147个中心随机入组371例既往二线治疗失败的晚期胃/胃食管 junction 癌患者,比较avelumab与医生选择的化疗。主要终点总生存未达优效(中位4.6 vs 5.0个月,HR=1.1,95%CI 0.9-1.4,P=0.81),无进展生存与客观缓解率亦无改善,但avelumab安全性更好。

要点

  • 三线单药avelumab较化疗未改善总生存(HR=1.1,P=0.81)。
  • avelumab组≥3级治疗相关不良事件发生率低于化疗(9.2% vs 31.6%)。
  • 该人群三线治疗仍需探索化疗以外的有效方案。

核心结论

  • 在晚期胃/胃食管 junction 癌三线治疗中,单药avelumab相比化疗未改善总生存和无进展生存,但安全性更易管理。

研究设计与样本

  • 随机、III期、开放标签JAVELIN Gastric 300试验,全球147个中心入组371例不可切除、复发、局部晚期或转移性胃/胃食管 junction 癌患者。
  • 患者随机接受avelumab 10 mg/kg静脉输注每2周一次,或医生选择的化疗(紫杉醇80 mg/m²第1、8、15天,或伊立替康150 mg/m²第1、15天,每4周为1周期),不适合化疗者接受最佳支持治疗。
  • 主要终点为总生存,次要终点包括无进展生存、客观缓解率和安全性。

主要发现

  • avelumab组与化疗组中位总生存分别为4.6个月和5.0个月(HR=1.1,95%CI 0.9-1.4,P=0.81),未达主要终点。
  • avelumab组与化疗组中位无进展生存分别为1.4个月和2.7个月(HR=1.73,95%CI 1.4-2.2,P>0.99),无改善。
  • avelumab组与化疗组客观缓解率分别为2.2%和4.3%。
  • 任何级别治疗相关不良事件在avelumab组发生90例(48.9%),化疗组131例(74.0%)。
  • ≥3级治疗相关不良事件在avelumab组发生17例(9.2%),化疗组56例(31.6%)。

临床怎么用

  • 不推荐在晚期胃/胃食管 junction 癌三线治疗中常规使用单药avelumab替代化疗。
  • 对于需三线治疗且重视安全性的患者,可结合此证据与患者偏好讨论,但疗效未优于化疗。
  • 该研究未提供生物标志物富集人群数据,临床决策不应据此扩大avelumab适应人群。

局限性

  • 研究为开放标签设计,化疗组包含医生选择的两种方案及最佳支持治疗,异质性可能影响比较。
  • 未报告生物标志物(如PD-L1)分层分析结果,无法识别潜在获益亚组。
  • 入组人群为全球多中心,但未报告地区亚组疗效,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There currently are no internationally recognised treatment guidelines for patients with advanced gastric cancer/gastro-oesophageal junction cancer (GC/GEJC) in whom two prior lines of therapy have failed. The randomised, phase III JAVELIN Gastric 300 trial compared avelumab versus physician's choice of chemotherapy as third-line therapy in patients with advanced GC/GEJC. PATIENTS AND METHODS: Patients with unresectable, recurrent, locally advanced, or metastatic GC/GEJC were recruited at 147 sites globally. All patients were randomised to receive either avelumab 10 mg/kg by intravenous infusion every 2 weeks or physician's choice of chemotherapy (paclitaxel 80 mg/m2 on days 1, 8, and 15 or irinotecan 150 mg/m2 on days 1 and 15, each of a 4-week treatment cycle); patients ineligible for chemotherapy received best supportive care. The primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety. RESULTS: A total of 371 patients were randomised. The trial did not meet its primary end point of improving OS {median, 4.6 versus 5.0 months; hazard ratio (HR)=1.1 [95% confidence interval (CI) 0.9-1.4]; P = 0.81} or the secondary end points of PFS [median, 1.4 versus 2.7 months; HR=1.73 (95% CI 1.4-2.2); P > 0.99] or ORR (2.2% versus 4.3%) in the avelumab versus chemotherapy arms, respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 90 patients (48.9%) and 131 patients (74.0%) in the avelumab and chemotherapy arms, respectively. Grade ≥3 TRAEs occurred in 17 patients (9.2%) in the avelumab arm and in 56 patients (31.6%) in the chemotherapy arm. CONCLUSIONS: Treatment of patients with GC/GEJC with single-agent avelumab in the third-line setting did not result in an improvement in OS or PFS compared with chemotherapy. Avelumab showed a more manageable safety profile than chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02625623.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Bang YJ, Ruiz EY, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018. PMID: 30052729. doi:10.1093/annonc/mdy264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。